[
    [
        {
            "time": "",
            "original_text": "华兰生物（002007）年报点评：疫苗业务快速放量，血制品业务有望企稳回升【东吴医药朱国广团队】",
            "features": {
                "keywords": [
                    "华兰生物",
                    "疫苗业务",
                    "快速放量",
                    "血制品业务",
                    "企稳回升"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华兰生物（002007）年报点评：疫苗业务快速放量，血制品业务有望企稳回升【东吴医药朱国广团队】",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "【华西医药崔文亮团队】《华兰生物点评报告：流感疫苗高速放量，血制品业务逐步恢复》",
            "features": {
                "keywords": [
                    "华兰生物",
                    "流感疫苗",
                    "高速放量",
                    "血制品业务",
                    "逐步恢复"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【华西医药崔文亮团队】《华兰生物点评报告：流感疫苗高速放量，血制品业务逐步恢复》",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "华兰生物（002007）：年报业绩符合预期，四价流感疫苗推动业绩高增",
            "features": {
                "keywords": [
                    "华兰生物",
                    "年报业绩",
                    "符合预期",
                    "四价流感疫苗",
                    "业绩高增"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华兰生物（002007）：年报业绩符合预期，四价流感疫苗推动业绩高增",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "【国元医药|点评】华兰生物2020年年报点评：业绩符合预期，流感疫苗实现高速增长",
            "features": {
                "keywords": [
                    "华兰生物",
                    "2020年年报",
                    "业绩符合预期",
                    "流感疫苗",
                    "高速增长"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【国元医药|点评】华兰生物2020年年报点评：业绩符合预期，流感疫苗实现高速增长",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "华鑫证券给予华兰生物推荐评级，流感疫苗高增长，业绩符合预期",
            "features": {
                "keywords": [
                    "华鑫证券",
                    "华兰生物",
                    "推荐评级",
                    "流感疫苗",
                    "高增长",
                    "业绩符合预期"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华鑫证券给予华兰生物推荐评级，流感疫苗高增长，业绩符合预期",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "东吴证券给予华兰生物买入评级，2020年年报点评：疫苗业务快速放量，血制品业务有望企稳回升",
            "features": {
                "keywords": [
                    "东吴证券",
                    "华兰生物",
                    "买入评级",
                    "疫苗业务",
                    "快速放量",
                    "血制品业务",
                    "企稳回升"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "东吴证券给予华兰生物买入评级，2020年年报点评：疫苗业务快速放量，血制品业务有望企稳回升",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "华金证券给予华兰生物买入评级，流感疫苗快速放量，血制品企稳恢复",
            "features": {
                "keywords": [
                    "华金证券",
                    "华兰生物",
                    "买入评级",
                    "流感疫苗",
                    "快速放量",
                    "血制品",
                    "企稳恢复"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华金证券给予华兰生物买入评级，流感疫苗快速放量，血制品企稳恢复",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "华兰生物(002007.SZ)：拟用不超过50亿元自有资金进行投资理财",
            "features": {
                "keywords": [
                    "华兰生物",
                    "投资理财",
                    "自有资金",
                    "50亿元"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "华兰生物(002007.SZ)：拟用不超过50亿元自有资金进行投资理财",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "医药周报：关注细分领域里质地优良、估值相对合理具有安全边际、增长确定性强的标的",
            "features": {
                "keywords": [
                    "医药周报",
                    "细分领域",
                    "质地优良",
                    "估值合理",
                    "安全边际",
                    "增长确定性"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药周报：关注细分领域里质地优良、估值相对合理具有安全边际、增长确定性强的标的",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        }
    ]
]